<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03830853</url>
  </required_header>
  <id_info>
    <org_study_id>240138</org_study_id>
    <nct_id>NCT03830853</nct_id>
  </id_info>
  <brief_title>The Impact of Coronary Chronic Total Occlusion Percutaneous Coronary Intervention on Culprit Vessel Physiology</brief_title>
  <acronym>IMPACT CTO 2</acronym>
  <official_title>The Impact of Coronary Chronic Total Occlusion Percutaneous Coronary Intervention on Culprit Vessel Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mid and South Essex NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mid and South Essex NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI),&#xD;
      a multitude of physiological and anatomical changes take place. Contemporary techniques such&#xD;
      as dissection/re-entry or lumen-lumen wiring may influence the immediate and longer term&#xD;
      follow up of these features. It is not known whether changes in this level of physiology and&#xD;
      anatomy in the context of CTO vessels correlate with each other, or with quality of life and&#xD;
      exercise capacity.&#xD;
&#xD;
      This study aims to take physiological measurements of absolute coronary flow, resistance and&#xD;
      pressure and intra-coronary imaging immediately after successful CTO PCI. The investigators&#xD;
      will relate these to each other and to the method of revascularisation, comparing changes in&#xD;
      these groups at three months follow up.&#xD;
&#xD;
      Quality of life measurements, and exercise testing will be carried out to see if there is a&#xD;
      relationship between physiological and anatomical changes with exercise capacity and quality&#xD;
      of life.&#xD;
&#xD;
      Results from this study could shed light on optimisation of CTO PCI procedural and clinical&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2015</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary flow</measure>
    <time_frame>3 months</time_frame>
    <description>change in coronary flow at baseline and follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in coronary resistance</measure>
    <time_frame>3 months</time_frame>
    <description>change in coronary absolute resistance at baseline and follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in coronary anatomy</measure>
    <time_frame>3 months</time_frame>
    <description>To identify intracoronary anatomical features between baseline and follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exercise work load</measure>
    <time_frame>3 months</time_frame>
    <description>Change in exercise work measured in METS (metabolic equivalents).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>change in quality measured by the validated Seattle angina seven question questionnaire from baseline to follow up. This is a scale based on 7 questions giving scores of 0-100 on physical limitation, angina, and quality of life, with the average of these scores giving a mean value also ranging from 0-100 of the overall summary score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary pressure measurements</measure>
    <time_frame>3 months</time_frame>
    <description>change in fractional flow reserve (FFR) at baseline and follow up</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>Successful CTO PCI achieved</arm_group_label>
    <description>Patients will have successful CTO PCI (chronic total occlusion percutaneous coronary intervention) followed by physiological and intracoronary imaging. These measurements will be repeated at a 3 month follow up angiogram procedure.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been selected for elective percutaneous coronary angioplasty (PCI) of&#xD;
        their chronic total occlusion (CTO) as part of routine standard of care will be approached&#xD;
        for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age&#xD;
&#xD;
          -  Presence of a coronary chronic total occlusion (CTO) scheduled for elective&#xD;
             percutaneous coronary angioplasty (PCI)&#xD;
&#xD;
          -  Evidence of viability in the CTO Territory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 year of age&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Known severe chronic kidney disease (creatinine clearance â‰¤30 mL/min), unless the&#xD;
             patient is on dialysis&#xD;
&#xD;
          -  Unable to receive antiplatelets or periprocedural anticoagulation&#xD;
&#xD;
          -  Contraindications to adenosine&#xD;
&#xD;
          -  Any study lesion characteristic resulting in the expected inability to deliver FD-OCT&#xD;
             catheter at the distal vessel post CTO PCI (e.g. moderate or severe vessel&#xD;
             calcification or tortuosity)&#xD;
&#xD;
          -  Pregnancy, planning pregnancy during study period, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Davies, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Basildon and Thurrock University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Essex Cardiothoracic Centre</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <zip>S16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Karamasis GV, Kalogeropoulos AS, Mohdnazri SR, Al-Janabi F, Jones R, Jagathesan R, Aggarwal RK, Clesham GJ, Tang KH, Kelly PA, Davies JR, Werner GS, Keeble TR. Serial Fractional Flow Reserve Measurements Post Coronary Chronic Total Occlusion Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2018 Nov;11(11):e006941. doi: 10.1161/CIRCINTERVENTIONS.118.006941.</citation>
    <PMID>30571203</PMID>
  </reference>
  <reference>
    <citation>Mohdnazri SR, Karamasis GV, Al-Janabi F, Cook CM, Hampton-Till J, Zhang J, Al-Lamee R, Dungu JN, Gedela S, Tang KH, Kelly PA, Davies JE, Davies JR, Keeble TR. The impact of coronary chronic total occlusion percutaneous coronary intervention upon donor vessel fractional flow reserve and instantaneous wave-free ratio: Implications for physiology-guided PCI in patients with CTO. Catheter Cardiovasc Interv. 2018 Sep 1;92(3):E139-E148. doi: 10.1002/ccd.27587. Epub 2018 Mar 22.</citation>
    <PMID>29569332</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTO - chronic total occlusion</keyword>
  <keyword>OCT - optical coherence tomography</keyword>
  <keyword>coronary physiology</keyword>
  <keyword>absolute flow</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

